|
|||||
|
|
WHO guide on the economic evaluation of influenza vaccination |
|
| Authors: | Anthony T. Newall Nathorn Chaiyakunapruk Philipp Lambach Raymond C. W. Hutubessy |
| Affiliation: | 1. School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales (UNSW), Sydney, Australia;2. School of Pharmacy, Monash University Malaysia, Selangor, Malaysia;3. Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand;4. Asian Centre for Evidence Synthesis in Population, Implementation and Clinical Outcomes (PICO), Health and Well‐being Cluster, Global Asia in the 21st Century (GA21) Platform, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia;5. Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland |
| Abstract: | Influenza is responsible for substantial morbidity and mortality across the globe, with a large share of the total disease burden occurring in low‐ and middle‐income countries (LMICs). There have been relatively few economic evaluations assessing the value of seasonal influenza vaccination in LMICs. The purpose of this guide is to outline the key theoretical concepts and best practice in methodologies and to provide guidance on the economic evaluation of influenza vaccination in LMICs. It outlines many of the influenza vaccine‐specific challenges and should help to provide a framework for future evaluations in the area to build upon. |
| Keywords: | guidelines influenza vaccines vaccine economics |